Mukka Proteins Secures US FDA Registration for Facility Through December 2027

Key numbers

Market Cap	₹754.2 CrSmall Cap
P/E Ratio	10.91xSector 26.29x
Promoter Holding	73.33%No Pledges
1-Year Return	0.48%Price Performance
Execution period	October 1, 2026 to December 31, 2027

Key highlights

• US FDA facility registration confirmed via Registrar Corp, Virginia, USA
• Registration validity spanning from October 1, 2026, to December 31, 2027
• Compliance aligned with Bioterrorism Act of 2002 and FDA Food Safety Modernization Act
• Strategic move to support business operations and US customer engagement
• Follows recent USDA and EU organic fertilizer certifications received in late 2026

FDA Registration Opens Access to American Markets

Mukka Proteins Limited has received a formal Certificate of Registration for its facility from the U.S. Food and Drug Administration (U.S. FDA).

Issued by Registrar Corp in Virginia, this registration confirms compliance with the Federal Food Drug and Cosmetic Act, the Bioterrorism Act of 2002, and the FDA Food Safety Modernization Act. The certification is active from October 1, 2026, and remains valid through December 31, 2027. This milestone is a critical prerequisite for the company to supply its products to customers and markets within the United States that mandate strict FDA facility registration.

Strategic Alignment with Global Export Standards

This US FDA registration follows a series of international regulatory successes for the Mangaluru-headquartered firm. In October 2026, the company received USDA NOP organic fertilizer attestations from ECOCERT, France, and obtained similar EU-standard attestations in September 2026. These certifications collectively broaden Mukka Proteins' access to high-value global markets.

With a management guidance targeting an annual revenue of over ₹3,000 crore by FY30, up from ₹1,449 crore in FY26, international market penetration via these regulatory clearances serves as a primary growth lever for the company's expanding food and beverage portfolio.

Financial Performance and Capacity Outlook

• Reported Q1 FY27 revenue of ₹489.65 crore, a 186.7% increase year-on-year
• Net profit for the latest quarter surged 1145% to reach ₹18.89 crore
• Operating profit margin improved to 9.8% compared to 8.5% in the previous year
• Valuation remains competitive with a PEG ratio of 0.18 and P/E of 10.91x
• Approved capacity expansion to 1,000 TPD to support growing order pipeline
• Joint venture order book stands at ₹474.89 crore for legacy leachate treatment

Official Statement on Business Impact

The registration is expected to support the Company's business operations and facilitate its engagement with customers and markets requiring U.S. FDA facility registration.

What to watch next

• Completion of 51% stake acquisition in Aqua Marine scheduled for January 31, 2027
• Execution progress on the ₹474.89 crore Bengaluru leachate treatment contract
• Scaling of Bengaluru BSF project following registration on the Verra Registry
• Progress toward the FY30 annual revenue guidance target of ₹3,000 crore

Mukka Proteins · financial snapshot

Share price	₹25.14
Market capitalisation	₹754.20 Cr
Revenue (annual)	₹1,449.45 Cr
Net profit (annual)	₹52.06 Cr
Revenue (latest quarter)	₹489.65 Cr+28.65% vs previous quarter
Net profit (latest quarter)	₹18.89 Cr-8.38% vs previous quarter
P/E (TTM)	10.91×Sector 26.29×
Promoter holding	73.33%0.00% QoQ
FII holding	1.7%Current quarter

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.